On September 25, 2025, the FDA approved Inluriyo (imlunestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This video explores the breakthrough, including clinical data from the EMBER-3 trial, as well as patient eligibility and dosing guidelines.
More Videos in ESR1 Mutated ER HER2 Advanced Breast Cancer Content Hub
Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
In this podcast, hosts Drs. Rahul and Rohit Gosain, and Jame Abraham, MD, Cleveland Clinic, highlight findings from the EMBER-3 study comparing imlunestrant alone versus imlunestrant combined with…
In an interview that took place at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, Timothy Yap, MBBS, PhD, medical oncologist, The University of Texas…
Patrick Neven, MD, Universitair Ziekenhuis Leuven, Leuven, Belgium, presents data from the EMBER-2 window-of-opportunity study, in which imlunestrant was given for about 2 weeks before surgery in women…
This webinar, focused on challenging cases in metastatic breast cancer, was moderated by Ashkan Lashkari, MD, oncologist at Wellness Oncology, California, and included expert panelists Rebecca A. Shatsky,…
Matthew P. Goetz, MD, Mayo Clinic, Rochester, Minnesota, describes how resistance to endocrine therapy often develops in ER-positive breast cancer through emergence of ESR1 mutations, which occur in…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
In this video, Virginia Kaklamani, MD, UT Health San Antonio, Texas, reviews the results of the EMBER-3 Phase 3 trial of imlunestrant, an oral SERD, in patients with…
Aditya Bardia, MD, MPH, director of translational research integration, UCLA, explains how metastatic estrogen receptor-positive breast cancers can develop ESR1 mutations. Donald McDonnell, PhD, research scientist, Duke University,…
Suzanne A. W. Fuqua, PhD, Baylor College of Medicine, explains that while the role of ESR1 mutations in primary breast cancer remains controversial, earlier studies have reported specific…
